Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Perturbations of 5-hydroxymethylcytosine patterning in hematologic malignancies.

Madzo J, Vasanthakumar A, Godley LA.

Semin Hematol. 2013 Jan;50(1):61-9. doi: 10.1053/j.seminhematol.2013.01.004. Review.

PMID:
23507484
2.

The TET2 interactors and their links to hematological malignancies.

Pan F, Weeks O, Yang FC, Xu M.

IUBMB Life. 2015 Jun;67(6):438-45. doi: 10.1002/iub.1389. Epub 2015 Jun 22. Review.

3.

Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas.

Müller T, Gessi M, Waha A, Isselstein LJ, Luxen D, Freihoff D, Freihoff J, Becker A, Simon M, Hammes J, Denkhaus D, zur Mühlen A, Pietsch T, Waha A.

Am J Pathol. 2012 Aug;181(2):675-83. doi: 10.1016/j.ajpath.2012.04.017. Epub 2012 Jun 9.

PMID:
22688054
4.

5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy.

Vasanthakumar A, Godley LA.

Cancer Genet. 2015 May;208(5):167-77. doi: 10.1016/j.cancergen.2015.02.009. Epub 2015 Mar 3. Review. Erratum in: Cancer Genet. 2016 Apr;209(4):177.

PMID:
25892122
5.

Ascorbate induces ten-eleven translocation (Tet) methylcytosine dioxygenase-mediated generation of 5-hydroxymethylcytosine.

Minor EA, Court BL, Young JI, Wang G.

J Biol Chem. 2013 May 10;288(19):13669-74. doi: 10.1074/jbc.C113.464800. Epub 2013 Apr 2.

6.

Robust quantitative assessments of cytosine modifications and changes in the expressions of related enzymes in gastric cancer.

Du C, Kurabe N, Matsushima Y, Suzuki M, Kahyo T, Ohnishi I, Tanioka F, Tajima S, Goto M, Yamada H, Tao H, Shinmura K, Konno H, Sugimura H.

Gastric Cancer. 2015 Jul;18(3):516-25. doi: 10.1007/s10120-014-0409-4. Epub 2014 Aug 7.

PMID:
25098926
7.

Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma.

Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, Xu W, Tan L, Hu Y, Zhan Q, Lee CW, Hu D, Lian BQ, Kleffel S, Yang Y, Neiswender J, Khorasani AJ, Fang R, Lezcano C, Duncan LM, Scolyer RA, Thompson JF, Kakavand H, Houvras Y, Zon LI, Mihm MC Jr, Kaiser UB, Schatton T, Woda BA, Murphy GF, Shi YG.

Cell. 2012 Sep 14;150(6):1135-46. doi: 10.1016/j.cell.2012.07.033.

8.

TET2 as an epigenetic master regulator for normal and malignant hematopoiesis.

Nakajima H, Kunimoto H.

Cancer Sci. 2014 Sep;105(9):1093-9. doi: 10.1111/cas.12484. Epub 2014 Sep 3. Review.

9.

Connections between TET proteins and aberrant DNA modification in cancer.

Huang Y, Rao A.

Trends Genet. 2014 Oct;30(10):464-74. doi: 10.1016/j.tig.2014.07.005. Epub 2014 Aug 14. Review.

10.

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Löwenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A.

Cancer Cell. 2010 Dec 14;18(6):553-67. doi: 10.1016/j.ccr.2010.11.015. Epub 2010 Dec 9.

11.

TET family proteins and 5-hydroxymethylcytosine in esophageal squamous cell carcinoma.

Murata A, Baba Y, Ishimoto T, Miyake K, Kosumi K, Harada K, Kurashige J, Iwagami S, Sakamoto Y, Miyamoto Y, Yoshida N, Yamamoto M, Oda S, Watanabe M, Nakao M, Baba H.

Oncotarget. 2015 Sep 15;6(27):23372-82.

12.

TET2-mediated 5-hydroxymethylcytosine induces genetic instability and mutagenesis.

Mahfoudhi E, Talhaoui I, Cabagnols X, Della Valle V, Secardin L, Rameau P, Bernard OA, Ishchenko AA, Abbes S, Vainchenker W, Saparbaev M, Plo I.

DNA Repair (Amst). 2016 Jul;43:78-88. doi: 10.1016/j.dnarep.2016.05.031. Epub 2016 May 24.

PMID:
27289557
13.

[TET2 as a gatekeeper for hematologic malignancies].

Muto H, Sakata-Yanagimoto M, Chiba S.

Rinsho Ketsueki. 2015 Jun;56(6):651-6. doi: 10.11406/rinketsu.56.651. Japanese.

PMID:
26256875
14.

Cytosine modifications in myeloid malignancies.

Meldi KM, Figueroa ME.

Pharmacol Ther. 2015 Aug;152:42-53. doi: 10.1016/j.pharmthera.2015.05.002. Epub 2015 May 5. Review.

PMID:
25956466
15.

Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.

Aslanyan MG, Kroeze LI, Langemeijer SM, Koorenhof-Scheele TN, Massop M, van Hoogen P, Stevens-Linders E, van de Locht LT, Tönnissen E, van der Heijden A, da Silva-Coelho P, Cilloni D, Saglio G, Marie JP, Tang R, Labar B, Amadori S, Muus P, Willemze R, Marijt EW, de Witte T, van der Reijden BA, Suciu S, Jansen JH.

Ann Hematol. 2014 Aug;93(8):1401-12. doi: 10.1007/s00277-014-2055-7. Epub 2014 Mar 29.

PMID:
24994606
16.

TET genes: new players in DNA demethylation and important determinants for stemness.

Mohr F, Döhner K, Buske C, Rawat VP.

Exp Hematol. 2011 Mar;39(3):272-81. doi: 10.1016/j.exphem.2010.12.004. Epub 2010 Dec 17. Review.

PMID:
21168469
17.
18.

Dysregulation of TET2 in hematologic malignancies.

Chiba S.

Int J Hematol. 2017 Jan;105(1):17-22. doi: 10.1007/s12185-016-2122-z. Epub 2016 Nov 15. Review.

PMID:
27848178
19.

Epigenetic alterations in hematopoietic malignancies.

Chung YR, Schatoff E, Abdel-Wahab O.

Int J Hematol. 2012 Oct;96(4):413-27. doi: 10.1007/s12185-012-1181-z. Epub 2012 Sep 27. Review.

PMID:
23015417
20.

The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.

Solary E, Bernard OA, Tefferi A, Fuks F, Vainchenker W.

Leukemia. 2014 Mar;28(3):485-96. doi: 10.1038/leu.2013.337. Epub 2013 Nov 13. Review.

PMID:
24220273

Supplemental Content

Support Center